Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Scientific World Journal |
Vol/bind | 2012 |
Sider (fra-til) | 170496 |
Antal sider | 4 |
ISSN | 2356-6140 |
DOI | |
Status | Udgivet - 2012 |
ID: 48498667